AZ’s Imfinzi joins the immunotherapy contest – pharmaphorum
|
AZ’s Imfinzi joins the immunotherapy contest
pharmaphorum The US regulator has approved AstraZeneca’s cancer immunotherapy, durvalumab – a blockbuster hopeful that could be the cornerstone of its new generation of oncology treatments. Under the brand name Imfinzi, durvalumab’s first FDA-approved use will be … |
|
PET Imaging May Predict Early Immunotherapy Response
Cancer Network Researchers provided a preclinical proof of concept for the use of granzyme B, a downstream effector of tumoral cytotoxic T cells, as an early biomarker for tumors responding to immunotherapy with checkpoint inhibitors. “In our study, we found a marker … |
The Oracle Dispatch |
US Stem Cell Inc (OTCMKTS:USRM) Explodes Higher Ahead of RMAT Decision
The Oracle Dispatch US Stem Cell Inc (OTCMKTS:USRM) is a penny player in the stem cell space that caught a massive jolt of bullish energy to start off this week. We didn’t see any clear new catalyst emerge, but the move likely hooks into the company’s near-term narrative, … Unproven stem cell therapies – promise versus evidenceBioNews US Stem Cell Inc (OTCMKTS:USRM) Extends Rise After Private Equity Firm Commits to Share PurchaseStreet Register US Stem Cell Inc (OTCMKTS:USRM) Receives Institutional Fund InjectionStockNewsUnion |
|
StemCONN Symposium Shows Connecticut is Leader in Stem Cell Research
Wesleyan Connection (blog) “Stem cell research continues to be an exciting and fast-paced field with new discoveries fueling prospects for new therapies based on regenerative medicine for a range of debilitating medical conditions, and Connecticut is at the leading edge of this … |
|
Novartis Gains Access to Celyad’s allogenic CAR–T cell patents
Labiotech.eu (blog) Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR–T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Celyad (CYAD), Novartis (NVS) Enter Non-Exclusive License for Allogeneic TCR-Deficient CAR–T CellsStreetInsider.com Novartis takes the long view on CAR–T, grabbing licenses on new tech for next-gen therapiesEndpoints News |